




































general	 gynaecological	 admission	 in	 order	 to	 reveal	 the	 families	 with	 tumour	
pathology	aggregation.	The	analysis	of	clinical-genealogical	data	of	the	females	
from	 such	 families	 determined	 that	 malignant	 tumours	 association	 in	 their	
families	 corresponded	 to	 familial	 cancer	 syndrome	 (Lynch	 syndrome	 II)	 or	
hereditary	 cancer.	Basing	on	 the	 results	of	 complex	 clinical	examination	of	73	
probands	who	had	malignant	 tumours	aggregation	 in	 their	 genealogical	 trees,	
malignant	 and	 premalignant	 processes	 in	 female	 reproductive	 system	 organs	
were	detected.	The	obtained	data	 indicated	 the	effectiveness	and	reasonability	
of	 questionnaires	 as	 a	 simple	 screening	 method	 during	 gynaecological	
admission	 to	 reveal	 the	 families	 with	 tumour	 pathology	 accumulation	 and	 to	
plan	 further	 extended	 individual	 examination	 for	 females	 from	 such	 families	












Malignancies	 prevention	 and	 early	 diagnostics	 are	 the	 most	 important	 social-medical	
problems	in	oncology.	This	thesis	relates	entirely	to	cancer	of	female	reproductive	system	organs	
(FRSO),	the	morbidity	rate	of	which	does	not	tend	to	decrease	 in	Ukraine	according	to	the	data	of	




tend	 significantly	 to	 reduce	 due	 to	 diagnostics	 of	 tumor	 processes	 at	 the	 late	 stages	 of	 their	
development.	Therefore,	from	the	position	of	anticancer	 strategies,	 the	priority	 is	 given	 	 both	 to	
prevention,	and	 to	early	diagnostics	of	precancer	and	cancer;	however	 these	problems	solving	 is	
complicated	by	the	lack	of	organized	systems	and	scientifically	based	programs.	At	the	same	time,	
one	 of	 the	 effective	 measures	 facilitating	 early	 diagnostics	 of	 precancer	 and	 cancer	 is	 the	
development	of	 screening	programs.	The	aim	of	 such	programs	 is	 to	detect	 the	disease	at	early	
stages	of	its	development,	when	the	symptoms	are	still	absent	and	curative	treatment	is	possible.	
One	can	differentiate	between	universal	and	 selective	 screenings;	 the	 latter	 is	performed	 in	 risk	
groups	 concerning	 the	 occurrence	 of	 specific	 disease	 [6-8].	 In	 our	 opinion,	 the	 achievements	 of	
clinical	oncogenetics,	where	theoretical	basics	of	genetics	and	molecular	biology	of	tumor	growth,	
and	also	practical	experience	of	oncologists	 regarding	hereditary	and	 family	cancer	 forms	of	 the	
cancer	 of	 breast,	 ovaries,	 uterus,	 colon	 and	 other	 tumors	 are	 integrated,	 may	 be	 included	 into	
selective	risk	programs	[3-5].		
The	objective	of	the	research	was	to	determine	the	role	of	clinical-genealogical	analysis	of	
genealogical	 trees	 for	determination	of	 families	with	 familial	cancer	syndrome,	and	as	a	stage	of	
genetic	screening	of	the	initial	forms	of	cancer	of	female	reproductive	system	organs.				
	
Material	 and	 methods	 of	 the	 research	 involved	 seven	 hundred	 and	 sixty	 clinical-





completed	 questionnaires	 for	 medical-genetic	 counseling	 by	 themselves.	 According	 to	 the	
questionnaires	 data	 in	 the	 families	 of	 73	 females	 (9.6%)	 the	 cancer	 patients	 were	 indicated	
comprising	172	persons	 in	 total.	 	Association	of	different	genesis	 tumors	 in	 families	became	 the	
reason	for	familial	cancer	syndrome	(FCS)	diagnostics.	Total	number	of	tumors	in	73	genealogical	




be	 seen	 from	 the	 Table	 1,	 the	 majority	 of	 tumors	 (60/33%)	 were	 FRSO	 cancers.	 Their	 numeric	
distribution	 demonstrated	 that	 breast	 cancer	 and	 uterine	 cancer	 prevailed	 (46.7%	 and	 30.0%,	
respectively),	 ovarian	 cancer	 (OC)	was	 less	 frequent	 (20.0%),	 and	uterine	 cancer	 comprised	 only	
3.3%.			
All	 the	 females	 that	sought	counseling	underwent	complete	examination	which	 included	
gynecologist’s	examination,	ultrasound	examination	of	small	pelvis	organs	and	abdominal	cavity,	
mammary	 and	 thyroid	 glands,	 mammography,	 fibrogastroscopy,	 colonoscopy,	 blood	 and	 urine	
analyses.	This	provided	an	opportunity	to	diagnose	pathological	processes	of	benign	(49/67.1%)	and	






on	 clinical	 diagnosis	 and	 age	 is	 presented	 in	 Table	 1,	 according	 to	 which	 the	 most	 frequently	
detected	 pathological	 processes	 were	 the	 ones	 in	 uterine	 corpus	 (23/31.9%)	 –	 uterine	 myoma,	
adenomyosis,	atypical	hyperplasia	of	endometrium,	 less	presented	were	the	processes	 in	uterine	
cervix	 (19/26.4%)	 -	 CIN2-3,	 endocervicosis,	 and	 chronic	 endocervicitis.	 The	 rate	 of	 females	 with	
ovarian	 and	 uterine	 tubes	 pathology	 (polycystosis	 and	 ovarian	 cysts)	 and	 mammary	 gland	




















































































































0-1А1,	3А	 31-39	 In	4	patients	 two	cases	
of	 uterine	 corpus	




in	 2	 patients	 1	 case	 of	














1А-2В	 43-51	 In	4	patients	BC	was	 in	
grandmother	 on	 the	
maternal	 side,	 in	
another	 2	patients	 –	 in	














1С	 36-51	 In	 I	 patient	 UCC	 in	
mother	 and	 OC	 in	
grandmothers	 on	 the	
maternal	 side,	 in	 2	
Relapse-free	 follow-up	



















1	 55	 CC	 in	 father	 and	





















1	 47	 Altogether	 2	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	












































trees	 (from	 them	 27	
relatives	 with	 cancer	
were	 on	 the	 maternal	
side	–	81.8%)	







	 All	 the	 females	 with	 detected	 oncologic	 and	 precancer	 pathology	 received	 treatment	
according	to	the	standards	established	in	Ukraine.	These	females	together	with	their	relatives	were	
assigned	 to	 the	groups	of	potential	genetic	risk	of	oncologic	pathology	development,	considering	






known	 to	 lead	 to	alteration	of	 sexual	hormones	 reception	and,	 in	 general,	 to	hormonal	balance	
alterations	 [1-5].	 	Such	changes	 in	hormonal	 reception	are	 the	cause	of	ovulatory	and	menstrual	
functions	 deteriorations	 that	 promote	 the	 development	 of	 such	 conditions	 as	 endometriosis,	
uterine	 myoma,	 hyperplastic	 processes	 in	 endometrium,	 ovarian	 cysts	 and	 polycystosis,	 and	
mammary	gland	fibroadenomatosis.	 	Fundamental	studies	demonstrated	two	major	mechanisms	
of	hormone	action:	promotor	 (physiological),	 that	 is	hormone	action	 is	directed	at	 cells	division	
stimulation,	and	genotoxic,	when	the	hormones	or	their	derivatives	affect	DNA	structure	inducing	
mutations	that	cause	genome	instability,	and	may	facilitate	tumor	grown	initiation	and	promotion	
[2,	 6-8].	 From	 the	 standpoint	 of	 the	 presented	 above	 information,	 the	 significance	 of	 hormonal	
homeostasis	disorder,	morphological	equivalents	of	which	are	changes	 in	 the	described	patients	
with	FCS	in	their	families,	has	extremely	important	clinical	significance.	This	is	a	reasonable	basis	
to	 include	 such	 patients	 into	 genetic	 risk	 groups	 of	 cancer	 development	 because	 it	 was	
demonstrated	 that	 in	FCS	cases	germinal	mutations	 in	 the	genes	 –	suppressors	of	tumor	growth	





The	 obtained	 results	 demonstrate	 the	 reasonability	 of	 application	 and	 introduction	 of	medical-
genetic	counseling	of	 females	 from	 the	 families	with	 tumor	pathology	aggregation.	The	obtained	









2. Clinical	 and	 genealogical	 analysis	 of	 the	 families	 and	 the	 knowledge	 of	 family	 and	
individual	 cancer	 history	 is	 an	 effective	 approach	 to	 reveal	 the	 families	 with	 FCS,	 and	
complex	 clinical-morphological	 examination	 of	 such	 persons	 allows	 detecting	 benign	
processes,	including	precancer	processes	and	tumor	processes	at	initial	stages.	
3. Knowledge	 of	 family	 and	 individual	 cancer	 history,	 along	 with	 testing	 of	 mutations	 of	
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